DRL-Header DRL-Header

X

Find Clinical Drug Pipelines for Healthy Volunteers

Loading...

All Data

Filters Filter
×
FILTER:
filter Study Phase
    filter Country
      filter News Type
        filter Company
          filter Product Type

            Active Filter(s):

            Product Type

            Development Status

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): ZYIL1

            Therapeutic Area: Healthy Volunteers Product Name: ZYIL1

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 07, 2020

            Details:

            ZYIL1 is a novel oral small molecule NLRP3 inhibitor candidate. Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers.